程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展

doi:10.35541/cjd.20200431

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (7): 633-636.doi: 10.35541/cjd.20200431

程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展

施雁庭¹ 黎皓² 郑捷¹ 曹华¹

¹上海交通大学医学院附属瑞金医院皮肤科，上海 200025；²上海交通大学医学院附属瑞金医院肿瘤科，上海 200025

收稿日期:2020-05-06 修回日期:2021-01-30 发布日期:2022-07-05
通讯作者: 曹华 E-mail:drcaohua@126.com
基金资助:
国家自然科学基金（81573037、81872523）；国家临床重点专科建设项目（2012649）；上海市科委医学引导类项目（134119a6100）；上海申康医院发展中心临床创新三年行动计划（16CR3084B）；上海交通大学医学院高峰学科——临床医学研究型医师（20172009）；上海市“医苑新星”杰出青年医学人才培养资助计划（2019）

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

Shih Yanting¹, Li Hao², Zheng Jie¹, Cao Hua¹

¹Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; ²Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2020-05-06 Revised:2021-01-30 Published:2022-07-05
Contact: Cao Hua E-mail:drcaohua@126.com
Supported by:
National Natural Science Foundation of China （81573037, 81872523）; National Clinical Key Subject Construction Project（2012649）; Shanghai Municipal Science and Technology Commission Medical Guide Project（134119a6100）; Clinical Research Plan of Shanghai Shen-kang Hospital Development Center （16CR3084B）; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support （20172009）; Shanghai "Rising Stars of Medical Talent" Youth Development Program-Outstanding Youth Medical Talents （2019）

摘要/Abstract

摘要： 【摘要】程序性细胞死亡蛋白（PD-1）与其配体（PD-L1）特异性结合后，具有共抑制/共刺激的免疫调控作用，可抑制T细胞活化、增殖及细胞因子分泌，参与肿瘤免疫、自身免疫及免疫耐受等。本文综述PD-1/PD-L1信号通路的组成结构、调控机制，以助于理解特发性炎症性肌病合并恶性肿瘤的免疫机制，寻找潜在的治疗靶点和诊断策略。

关键词: 程序性细胞死亡受体1, 肌炎, 肿瘤, 免疫检查点抑制剂, 抗转录中介因子1-γ抗体

Abstract: 【Abstract】 After the specific binding of programmed death-1 （PD-1） to programmed death ligand 1（PD-L1）, the PD-1/PD-L1 complex can exert a co-suppressive/co-stimulatory immunoregulatory effect, which can inhibit the activation and proliferation of T cells and their cytokine secretion, and play a key role in tumor immunity, autoimmunity and immune tolerance. This review summarizes structures and regulatory mechanisms of the PD-1/PD-L1 signaling pathway, aimming to facilitate the understanding of immune pathogenesis of idiopathic inflammatory myopathies complicated by malignant tumors, and to seek potential therapeutic targets and diagnostic strategies.

Key words: Programmed cell death 1 receptor, Myositis, Neoplasms, Immune checkpoint inhibitors, Anti-transcription intermediary factor 1-γ antibody

施雁庭黎皓郑捷曹华. 程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展[J]. 中华皮肤科杂志, 2022,55(7):633-636. doi:10.35541/cjd.20200431

Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies[J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636.doi:10.35541/cjd.20200431

参考文献 34

［1］	Thompson C, Piguet V, Choy E. The pathogenesis of dermatomyositis［J］. Br J Dermatol, 2018,179（6）:1256⁃1262. doi: 10.1111/bjd.15607.
［2］	Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7⁃related molecule, B7⁃H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies［J］. FASEB J, 2003,17（13）:1892⁃1894. doi: 10. 1096/fj.03⁃0039fje.
［3］	Xiaoyu D, Yunxia W, Qi F, et al. Expression of B7⁃homolog 1 in Polymyositis［J］. Ann Clin Lab Sci, 2011,41（2）:154⁃160.
［4］	Chen H, Peng Q, Yang H, et al. Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis［J］. J Rheumatol, 2018,45（6）:835⁃840. doi: 10.3899/jrheum.170544.
［5］	Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory pathways in the B7⁃CD28 ligand⁃receptor family［J］. Immunity, 2016,44（5）:955⁃972. doi: 10.1016/j.immuni.2016.05.002.
［6］	Chen L, Flies DB. Molecular mechanisms of T cell co⁃stimulation and co⁃inhibition［J］. Nat Rev Immunol, 2013,13（4）:227⁃242. doi: 10.1038/nri3405.
［7］	Francisco LM, Sage PT, Sharpe AH. The PD⁃1 pathway in tolerance and autoimmunity［J］. Immunol Rev, 2010,236:219⁃242. doi: 10.1111/j.1600⁃065X.2010.00923.x.
［8］	Kuol N, Stojanovska L, Nurgali K, et al. PD⁃1/PD⁃L1 in disease［J］. Immunotherapy, 2018,10（2）:149⁃160. doi: 10.2217/imt⁃2017⁃0120.
［9］	Lind H, Gameiro SR, Jochems C, et al. Dual targeting of TGF⁃β and PD⁃L1 via a bifunctional anti⁃PD⁃L1/TGF⁃βRII agent: status of preclinical and clinical advances［J］. J Immunother Cancer, 2020,8（1）. doi: 10.1136/jitc⁃2019⁃000433.
［10］	Park BV, Freeman ZT, Ghasemzadeh A, et al. TGFβ1⁃mediated SMAD3 enhances PD⁃1 expression on antigen⁃specific T cells in cancer［J］. Cancer Discov, 2016,6（12）:1366⁃1381. doi: 10.1158/2159⁃8290.CD⁃15⁃1347.
［11］	Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF⁃beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down⁃regulation of Smad7［J］. J Immunol, 2004,172（9）:5149⁃5153. doi: 10.4049/jimmunol.172. 9.5149.
［12］	Garo LP, Ajay AK, Fujiwara M, et al. Smad7 controls immunoregulatory PDL2/1⁃PD1 signaling in intestinal inflammation and autoimmunity［J］. Cell Rep, 2019,28（13）:3353⁃3366.e5. doi: 10.1016/j.celrep.2019.07.065.
［13］	Nishimura H, Nose M, Hiai H, et al. Development of lupus⁃like autoimmune diseases by disruption of the PD⁃1 gene encoding an ITIM motif⁃carrying immunoreceptor［J］. Immunity, 1999,11（2）:141⁃151. doi: 10.1016/s1074⁃7613（00）80089⁃8.
［14］	Greisen SR, Rasmussen TK, Stengaard⁃Pedersen K, et al. Increased soluble programmed death⁃1 （sPD⁃1） is associated with disease activity and radiographic progression in early rheumatoid arthritis［J］. Scand J Rheumatol, 2014,43（2）:101⁃108. doi: 10.3109/03009742.2013.823517.
［15］	Kobayashi M, Kawano S, Hatachi S, et al. Enhanced expression of programmed death⁃1 （PD⁃1）/PD⁃L1 in salivary glands of patients with Sjögren′s syndrome［J］. J Rheumatol, 2005,32（11）:2156⁃2163.
［16］	Dani L, Ian Che W, Lundberg IE, et al. Overall and site⁃specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016［J］. Semin Arthritis Rheum, 2021,51（1）:331⁃337. doi: 10.1016/j.semarthrit.2020.12. 009.
［17］	Hsu JL, Liao MF, Chu CC, et al. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan［J］. Sci Rep, 2021,11（1）:4545. doi: 10.1038/s41598⁃021⁃83729⁃5.
［18］	Zidane M, Dressler C, Nast A, et al. Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis［J］. Br J Dermatol, 2020,183（1）:186⁃188. doi: 10.1111/bjd.18948.
［19］	Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody［J］. Brain, 2016,139（Pt 8）:2131⁃2135. doi: 10.1093/brain/aww054.
［20］	McHugh NJ, Tansley SL. Autoantibodies in myositis［J］. Nat Rev Rheumatol, 2018,14（5）:290⁃302. doi: 10.1038/nrrheum.2018.56.
［21］	De Vooght J, Vulsteke JB, De Haes P, et al. Anti⁃TIF1⁃γ autoantibodies: warning lights of a tumour autoantigen［J］. Rheumatology （Oxford）, 2020,59（3）:469⁃477. doi: 10.1093/rheumatology/kez572.
［22］	Aussy A, Boyer O, Cordel N. Dermatomyositis and immune⁃mediated necrotizing myopathies: a window on autoimmunity and cancer［J］. Front Immunol, 2017,8:992. doi: 10.3389/fimmu.2017.00992.
［23］	Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion［J］. Science, 2011,331（6024）:1565⁃1570. doi: 10.1126/science. 1203486.
［24］	Labrador⁃Horrillo M, Selva⁃O′Callaghan A. Cancer⁃associated dermatomyositis: does the PD⁃1 checkpoint pathway play a role?［J］. J Rheumatol, 2018,45（6）:731⁃732. doi: 10.3899/jrheum. 180007.
［25］	Knauss S, Preusse C, Allenbach Y, et al. PD1 pathway in immune⁃mediated myopathies: pathogenesis of dysfunctional T cells revisited［J］. Neurol Neuroimmunol Neuroinflamm, 2019,6（3）:e558. doi: 10.1212/NXI.0000000000000558.
［26］	Pinal⁃Fernandez I, Ferrer⁃Fabregas B, Trallero⁃Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer⁃associated myositis［J］. Rheumatology （Oxford）, 2018,57（2）:388⁃396. doi: 10.1093/rheumatology/kex413.
［27］	Yu C, Ding Z, Liang H, et al. The roles of TIF1γ in cancer［J］. Front Oncol, 2019,9:979. doi: 10.3389/fonc.2019.00979.
［28］	Wang L, Yang H, Lei Z, et al. Repression of TIF1γ by SOX2 promotes TGF⁃β⁃induced epithelial⁃mesenchymal transition in non⁃small⁃cell lung cancer［J］. Oncogene, 2016,35（7）:867⁃877. doi: 10.1038/onc.2015.141.
［29］	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
［30］	Abril⁃Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors［J］. Cancer Cell, 2017,31（6）:848⁃848.e1. doi: 10. 1016/j.ccell.2017.05.010.
［31］	Shah M, Tayar JH, Abdel⁃Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy［J］. Semin Arthritis Rheum, 2019,48（4）:736⁃740. doi: 10.1016/j.semarthrit.2018.05.006.
［32］	Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti⁃striated muscle antibody following single dose of ipilimumab⁃nivolumab therapy in a patient with metastatic melanoma［J］. Case Reports Immunol, 2019,2019:2539493. doi: 10.1155/2019/2539493.
［33］	Marano AL, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti⁃programmed cell death 1 therapy［J］. Br J Dermatol, 2019,181（3）:580⁃583. doi: 10.1111/bjd.17245.
［34］	Blank CU, Haining WN, Held W, et al. Defining ′T cell exhaustion′［J］. Nat Rev Immunol, 2019,19（11）:665⁃674. doi: 10.1038/s41577⁃019⁃0221⁃9.

[1]	张诗敏胡赟赟赵肖庆杜联军曹华郑捷. 影像技术在皮肌炎诊断和病情评估中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 637-640.
[2]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[3]	冯华高英姝李清孙联文. 细胞力学在皮肤科的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 641-644.
[4]	夏利杨林洪许丽孙文国于亮翟婉芳王东霞邝小湾. 微小RNA-181b-5p对皮肤黑素瘤细胞株增殖和侵袭的作用及机制研究[J]. 中华皮肤科杂志, 2022, 55(7): 588-595.
[5]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[6]	刘影易秀莉叶竹标高天文朱冠男. 源于中国人转移性黑素瘤细胞株的建立及其生物学特性研究[J]. 中华皮肤科杂志, 2022, 55(5): 375-381.
[7]	高妮刘宇王雷刘玲高天文李凯. 孤立性真皮黑素瘤5例临床及组织病理分析[J]. 中华皮肤科杂志, 2022, 55(5): 408-410.
[8]	魏凤张晓光韩文瑞荣蓉王丽娟赵伊珂李艳玲. 【开放获取】局部皮瓣联合修复鼻及鼻周非黑素瘤皮肤癌Mohs显微外科手术后较大缺损11例效果分析[J]. 中华皮肤科杂志, 2022, 0(4): 20210119-e20210119.
[9]	李艳张选奋张文芳 . 基于Wnt/β联蛋白信号通路探讨EphB2抑制剂对皮肤鳞状细胞癌的影响及作用机制[J]. 中华皮肤科杂志, 2022, 55(4): 321-328.
[10]	徐聪聪陈浩. PI3K/Akt/mTOR信号通路在皮肤鳞状细胞癌中的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 264-267.
[11]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[12]	岳超, 罗显雁, 王涛, 段梦莹, 戴叶芹, 彭建中. 纵向切口横向缝合法在下眼睑缘五边形全层缺损修复中的应用[J]. 中华皮肤科杂志, 2022, 55(2): 159-161.
[13]	葛新红, 焦亚宁, 葛明昊, 马迎东, 石越, 王禹, 刘玲玲. 沉默信息调节因子1、3和缺氧诱导因子1α在皮肤鳞状细胞癌组织和细胞中的表达[J]. 中华皮肤科杂志, 2022, 55(2): 116-122.
[14]	包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156.
[15]	闫娜, 杨丽娟, 赵婵, 刘燕, 曾维惠, 耿松梅, 谭宣丰. 皮下组织蒂隧道插入皮瓣在鼻翼缺损修复中的应用[J]. 中华皮肤科杂志, 2022, 55(2): 161-163.

程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

Metrics

本文评价

推荐阅读 10